Drug-Drug Interaction Study With PF-05089771

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will test the potential for PF-05089771 to interact with a cocktail of drugs

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

NCT00964106

Drug Interactions

COMPLETED PHASE1

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

NCT05594615

COVID-19

COMPLETED PHASE1

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

NCT03187496

NASH

COMPLETED PHASE1

The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity

NCT01361217

Drug-Drug Interaction Healthy Volunteers

COMPLETED NA

Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

NCT03195946

Drug Reactions

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active tratment

Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771

Group Type EXPERIMENTAL

Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771

Intervention Type DRUG

PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771

PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and/or female subjects between the ages of 18 and 55 years;
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs);

Exclusion Criteria

* Any condition possibly affecting drug absorption
* History of regular alcohol consumption
* Screening supine blood pressure \>140 mm Hg (systolic) or \>90 mm Hg (diastolic),
* Consumption of coffee, cola or other caffeine containing drinks

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes